[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"treatment-effectiveness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:treatment-effectiveness":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100652021","efficacy-of-cognitive-behavioural-therapy-for-insomnia-and-bright-light-therapy-in-adolescents-with-adhd-insomnia-and-evening-chronotype-100652021",false,"NCT07767617","Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD, Insomnia, and Evening Chronotype","Efficacy of Cognitive Behavioural Therapy for Insomnia and Bright Light Therapy in Adolescents With ADHD and Comorbid Insomnia and Evening Chronotype: A Randomised, Assessor Blind, Parallel-group Trial","Inclusion criteria:\n\nAn adolescent who meets the following criteria will be eligible for taking part in this study:\n\n1. aged 10-24 years old;\n2. ADHD diagnosis confirmed by DISC-IV;\n3. DSM-5 diagnosis of insomnia disorder with an ≥ 9 (suggested cut-off for adolescents);\n4. Being classified as evening chronotype according to the score on the Horne-Östberg Morning-Eveningness Questionnaire (MEQ) and having a sleep onset time of 11:15pm or later for 12 year olds, 11:30pm or later for 13-14 year olds, 12:00am or later for 15-17 years old \\[64\\], 10:56pm or later for 18-24 years old at least 3 nights per week in the past 3 months and as confirmed by a 7-day sleep diary;\n5. Written informed consent from the participant and their parent\u002Fguardian (for those aged under 18);\n6. Being able to comply with the study protocol;\n7. Either not on ADHD medication or stabilized on medications for at least 6 months.\n\nExclusion criteria:\n\nAn adolescent who meets one or more of the following criteria will be excluded from the study:\n\n1. Substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia, ASD, organic mental disorders, or intellectual disabilities;\n2. Prominent medical condition affecting sleep (e.g., severe eczema, GERD);\n3. Clinically diagnosed sleep disorder other than insomnia disorder, such as narcolepsy, sleep-disordered breathing, and restless leg syndrome;\n4. Concurrent, regular use of medications(s) known to affect sleep continuity and quality including both prescribed medications (e.g., hypnotics, steroids) and over-the-counter OTC medications (e.g., melatonin, Traditional Chinese Medicine, TCM), except for ADHD stimulants;\n5. Ongoing psychological treatment for sleep problems;\n6. With hearing or speech deficit;\n7. Having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt).","ALL","10 Years","24 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","Attention-deficit\u002Fhyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by persistent inattention, hyperactivity, and impulsivity. In adolescents and young people, ADHD is commonly accompanied by insomnia and circadian delay. These co-occurring sleep and circadian disturbances may negatively affect daytime functioning and overall clinical outcomes. Although cognitive behavioural therapy for insomnia (CBT-I) is considered the first-line treatment for insomnia, and bright light therapy may help address circadian issues, their efficacy in adolescents with ADHD and comorbid insomnia and eveningness remains unexplored. This study aims to evaluate whether CBT-I, with or without bright light therapy, improves insomnia, sleep, and circadian as well as other clinical outcomes, and cognitive functioning in youths with ADHD and whether these interventions can also lead to improvements in mood and other clinical symptoms, as well as cognitive functioning.",[27,28,29,30,31],"Insomnia","ADHD","Eveningness","Chronotype","Treatment Effectiveness","NOT_YET_RECRUITING","2026-08-11",{"date":35,"type":36},"2026-08-17","ACTUAL",{"date":38,"type":21},"2026-08-10",{"date":40,"type":21},"2029-08-31",{"name":42,"class":43},"The University of Hong Kong","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100500245","early-intervention-to-prevent-lower-limb-lymphedema-of-gynecological-malignancy-100500245","NCT05793749","Early Intervention to Prevent Lower Limb Lymphedema of Gynecological Malignancy","Early Intervention to Prevent Gynecological Malignant Tumors Clinical Study of Lymphedema of the Lower Limbs in Patients With Radiotherapy After Lymphadenectomy","Inclusion Criteria:\n\n1.Gynecologic oncology patients undergoing radiotherapy after lymph node surgery who voluntarily participate in this study and sign an informed consent form.\n\n2.18 to 60 years old. 3.Eastern Cooperative Oncology Group（ECOG) score less than 2. 4.Expected survival time greater than 3 years. 5.Hemoglobin(Hb) greater than or equal to 70 g\u002FL, white blood cells (WBC)greater than or equal to 3.5 × 109 \u002FL, neutrophils(ANC)greater than or equal to 1.5 × 109 \u002FL, platelets (PLT)greater than or equal to 80 × 109 \u002FL.\n\n6.serum alamine aminotransferase(ALT) and glutamic oxalacetic transaminase(AST) less than 2 times the normal value and creatinine less than 1.5 times the normal value, albumin greater than or equal to 35g\u002FL.\n\n7.Women of childbearing potential must have had a pregnancy test (serum or urine) within 7 days prior to enrollment and have a negative result and be willing to use an appropriate method of contraception for the duration of the trial.\n\n8.Ability to comply with the trial protocol, as judged by the investigator.\n\nExclusion Criteria:\n\n1. Lymphedema and deep vein thrombosis of the lower extremities were clearly diagnosed;\n2. Acute infection of any kind;\n3. Patients with lower extremity edema;\n4. pregnancy, menstrual period;\n5. Recent major abdominal surgery (determined by the investigator);\n6. Radiation colitis, cystitis, intestinal infection, small bowel or large bowel diverticulitis or diverticulitis;\n7. Liver fibrosis;\n8. Abdominal aortic aneurysm;\n9. acute phlebitis;\n10. Severe arterial obstructive disease, arterial ulcer, ABPI (ankle-brachial blood pressure index) greater than 1.3 and less than 0.5;\n11. Severe peripheral neuropathy;\n12. Poor control of hypertension, poor control of stroke and diabetes, and severe bronchial asthma;\n13. Patients who cannot understand the experimental content and cannot cooperate and those who refuse to sign the informed consent;\n14. Those with concomitant diseases or other special circumstances that seriously endanger the patient's safety or affect the patient's completion of the study.","FEMALE","18 Years","60 Years",{"count":56,"type":21},400,[24],"This study is a prospective, randomized, controlled clinical trial of a single center in China and plans to enroll 400 patients.\n\n1. Patients with diagnosed gynecological malignancies who underwent pelvic and abdominal lymphadenectomy and required pelvic radiotherapy;\n2. Random grouping (A:B=3:1): A. Prophylactic lymphoedema treatment; B. Standard care group;\n3. Preventive lymphedema health education was given to patients with gynecological malignant tumors without contraindications before surgery. All patients were randomly divided into an intervention group and a nonintervention group. The intervention group received preventive lymphedema treatment twice a week. 10 times, and the interval between the two treatments was not less than 48 hours and not more than 2 weeks. The intervention measures included four parts: manual lymphatic drainage, skin care, functional exercise, and wearing lymphedema preventive compression stockings. In the nonintervention group, knowledge education and telephone follow-up were routinely conducted.\n4. All patients were evaluated for edema, lymphedema symptoms and quality of life 1 day before radiotherapy, every Friday during radiotherapy and every 3 months thereafter. Bioelectrical impedance measurement and leg diameter measurement were used to evaluate edema, the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) was used to evaluate lymphedema symptoms, and the EORTC Quality of Life Scale (QLQ-C30) was used to evaluate quality of life. followed up to 2 years after the end of lymphedema prophylaxis.",[60,61,62,31],"Uterine Cervical Neoplasms","Endometrial Neoplasms","Lymphedema",[62,61,60,31],"RECRUITING","2023-03-20",{"date":67,"type":36},"2023-03-31",{"date":69,"type":21},"2023-04-01",{"date":71,"type":21},"2026-07-29",{"name":73,"class":43},"Chongqing University Cancer Hospital"]